野村研究报告指，预期石药集团(01093.HK) 今年首季盈利升47%，收入则跌2%至88亿元人民币(下同)。成品药方面，该行料3大药物种类，包括中枢神经系统(CNS)、肿瘤及传染病药物的销售额将分别按年跌8%、63%及26%，基于去年同期的高基数，以及肿瘤药物面临价格压力。但该行认为去年两项授权交易的潜在收入确认将可抵消药品销售额下降。利润率方面，该行料毛利率为75.7%，由药物业务毛利率68%...
Source Link野村研究报告指，预期石药集团(01093.HK) 今年首季盈利升47%，收入则跌2%至88亿元人民币(下同)。成品药方面，该行料3大药物种类，包括中枢神经系统(CNS)、肿瘤及传染病药物的销售额将分别按年跌8%、63%及26%，基于去年同期的高基数，以及肿瘤药物面临价格压力。但该行认为去年两项授权交易的潜在收入确认将可抵消药品销售额下降。利润率方面，该行料毛利率为75.7%，由药物业务毛利率68%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.